Tumor heterogeneity poses a significant challenge in cancer diagnosis and treatment for several reasons, including misdiagnosis, inappropriate treatment decisions, and treatment resistance.

Melanoma stands out with highest mutation frequency among human cancers — this combined with the low prognosis rate makes it urgent to address it’s heterogeneity.

Asymmetry – two very different looking halves.

Border – Irregular, notched or scalloped borders.

Color – Many colors or uneven distribution.

Diameter – A mole larger than 6 millimeters.

Evolving – Grows in size.

Lipid-based delivery systems have a more established track record in clinical applications, such as lipid nanoparticle-based mRNA vaccines, which gained prominence during the COVID-19 pandemic. This familiarity with regulatory pathways and safety profiles will expedite the clinical translation of lipid-based CRISPR/Cas9 therapies for tumor heterogeneity.

Based off databases research like GEPIA and a literature search of published papers, we narrowed down candidates from thousands to a few key genes that have a large impact on tumor heterogeneity in Melanoma.

Our research is currently ongoing. We’re aiming for a clinical beta release of our product in 2025. We’ll keep all of you updated through our newsletter.